Virax Biolabs VRAX
NASDAQ VRAX
$2.24 +0.06 (+2.56%)
At close: Oct 1, 2026 · 4:00 PM EDT

Virax Biolabs (VRAX) Accumulated Expenses (2021 - 2026)

Updated

Virax Biolabs (VRAX) recorded Accumulated Expenses of $157,662 in fiscal Q4 2026 (quarter ended Mar 31, 2026), up 24.6% from $126,543 a year earlier.

Analysis

Virax Biolabs (VRAX) Accumulated Expenses (2021 - 2026) Analysis & Trends

Starting with fiscal Q4 2021, Virax Biolabs' Accumulated Expenses history includes 6 quarters.

  • Annual Accumulated Expenses has a five-year compound annual growth rate of -10.8% (FY2021 to FY2026).
  • Across earlier fiscal years, Accumulated Expenses came in at $126,543 in FY2025 (+100.5%), $63,120 in FY2024 (-48.3%), $121,991 in FY2023 (-54.7%) and $268,999 in FY2022 (-3.8%).
  • The fiscal Q4 2026 figure is the highest quarterly Accumulated Expenses since fiscal Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 249.71 Bn 228.86 Bn 4.88 Bn
2 Abbott Laboratories 171.00 Bn 142.08 Bn 7.27 Bn
3 Danaher 155.79 Bn 139.61 Bn 3.61 Bn
4 Intuitive Surgical 143.91 Bn 123.46 Bn 1.96 Bn
5 Medtronic 110.42 Bn 76.29 Bn 6.34 Bn
6 Stryker 105.71 Bn 91.82 Bn 4.50 Bn
7 Boston Scientific 63.26 Bn 58.27 Bn 3.85 Bn
8 Edwards Lifesciences 49.80 Bn 33.91 Bn 1.35 Bn
9 Becton Dickinson 48.78 Bn 45.93 Bn 2.32 Bn
10 Virax Biolabs 866,746.23 -20.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 157,662.00
Mar 31, 2025 126,543.00
Mar 31, 2024 63,120.00
Mar 31, 2023 121,991.00
Mar 31, 2022 268,999.00
Mar 31, 2021 279,481.00
API Access

Virax Biolabs Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=VRAX&period=max&api_key=YOUR_API_KEY